COVID-19 Vaccine Skycovion Among Raft Of New EU Filings
Executive Summary
EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.
You may also be interested in...
New EU Filings
Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Janssen's talquetamab for the treatment of patients with relapsed or refractory multiple myeloma is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Pharming’s leniolisib for treating the rare immunodeficiency APDS is among the new drugs that the European Medicines Agency has started reviewing for potential EU marketing approval.